Finance

Lists
CLYM:NASDAQ
Climb Bio Inc
$9.19
-0.97%
(-0.090) 1D
$9.03
-1.76% (-0.16)
After hours
Closed: Nov 20, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLYM...
Open
$8.98
High
$9.40
Low
$8.90
Mkt. cap
539.80M
Avg. vol.
1.15M
Volume
770.18K
52-wk high
$18.33
52-wk low
$1.64
EPS
-$0.82
Beta
0.04
Shares outstanding
58.74M
No. of employees
29
Open
$8.98
High
$9.40
Low
$8.90
Mkt. cap
539.80M
Avg. vol.
1.15M
Volume
770.18K
52-wk high
$18.33
52-wk low
$1.64
EPS
-$0.82
Beta
0.04
Shares outstanding
58.74M
No. of employees
29
News stories
From web sources and news partners
About Climb Bio Inc
CEO-
Employees29
Founded2018
HeadquartersWellesley Hills, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 13 analysts giving stock ratings to CLYM in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CLYM in the last 3 months.
Highest
Current $9.19
$40.00 (+335.26%)
Average
$28.83 (+213.71%)
Lowest
$23.00 (+150.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Nevin Varghese
RBC Capital
Buy
Maintained
$23.00
+150.3%
11/18/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Maintained
$26.00
+182.9%
11/10/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$30.00
+226.4%
11/09/2026
Danielle Brill
Truist Financial
Buy
Maintained
$25.00
+172%
11/06/2026
Laura Chico
Wedbush
Buy
Maintained
$27.00
+193.8%
11/06/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$25.00
+172%
11/06/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$35.00
+280.8%
11/05/2026
Julian Harrison
BTIG
Buy
Maintained
$32.00
+248.2%
11/04/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$40.00
+335.3%
10/30/2026
David Hoang
Deutsche Bank
Buy
Initiated
$28.00
+204.7%
10/20/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$30.00
+226.4%
09/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$25.00
+172%
09/03/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/03/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$18.00
+95.9%
08/07/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
06/24/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
06/12/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$21.00
+128.5%
05/06/2026
Geulah Livshits
Chardan Capital
Buy
Initiated
$22.00
+139.4%
05/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$18.00
+95.9%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13.74M
9.37M
9.71M
11.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.56M
5.84M
5.64M
5.85M
Operating expense
19.30M
15.21M
15.36M
16.89M
Total operating expenses
19.30M
15.21M
15.36M
16.89M
Operating income
-19.30M
-15.21M
-15.36M
-16.89M
Other non operating income
-
-
-
-
EBT including unusual items
-17.52M
-13.72M
-13.50M
-14.57M
EBT excluding unusual items
-17.52M
-13.72M
-13.50M
-14.57M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.52M
-13.72M
-13.50M
-14.57M
Net profit margin
-
-
-
-
Earnings per share
-0.26
-0.20
-0.18
-0.18
Interest and investment income
1.83M
1.51M
1.86M
2.32M
Interest expense
-
-
-
-
Net interest expenses
1.83M
1.51M
1.86M
2.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.27M
-15.17M
-15.33M
-16.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps